Compounded GLP-1 in 2026: Where Things Stand
Compounded semaglutide and tirzepatide became a mass-market phenomenon during the shortage years. With those shortages officially resolved, the legal ground under routine GLP-1 compounding has shifted. This is where the landscape actually stands in 2026, what remains permitted, and what to weigh.
The 60-second version
Compounded GLP-1s scaled during 2022–2024 because official FDA shortages opened a legal window for pharmacies to prepare copies. That window closes when the shortage does, and the tirzepatide and semaglutide shortages were declared resolved across 2024–2025. As a result, routine at-scale compounding to substitute for available branded product no longer has its former legal basis. Narrow clinical-need exceptions under 503A remain, but low price and convenience are not lawful justifications once the drug is commercially available. Products sold as ‘research’ GLP-1 sit outside the pharmacy system entirely and are a separate, higher-risk category.
Key takeaways
- Compounding scaled because official shortages created a legal window; that window tracks the shortage.
- The FDA declared the tirzepatide and semaglutide shortages resolved across 2024–2025.
- Routine mass-compounding of GLP-1 copies has lost its shortage-based legal basis in 2026.
- Narrow 503A clinical-need exceptions remain; cost and convenience are not, by themselves, lawful bases.
- Documented risks included dosing errors, unstudied salt forms, and variable sterile-prep quality.
- ‘Research’ semaglutide or tirzepatide sits outside the pharmacy system and is a separate, higher-risk category.
What "compounded" means, and why it exploded
A compounded drug is prepared by a pharmacy for an individual patient rather than manufactured and packaged by the brand-name company. Compounding is a legitimate, long-standing part of pharmacy, but it exists under specific rules. During 2022–2024, semaglutide and tirzepatide were in official FDA shortage, and that shortage status opened a legal window: while a drug is on the shortage list, compounders may prepare copies to meet demand the manufacturer cannot. Demand was enormous, coverage gaps were wide, and compounded versions were far cheaper, so the practice scaled rapidly into telehealth and clinic channels.
The turning point: shortages resolved
That window is defined by the shortage, and the shortage has closed. As the FDA declared the tirzepatide and then semaglutide shortages resolved across 2024–2025, the central legal basis for mass-compounding these molecules fell away, with wind-down periods for pharmacies to stop. This is the most important fact about the 2026 landscape: routine, at-scale compounding of GLP-1 copies to substitute for available branded product no longer has the shortage justification it relied on. The change is regulatory, not a judgment that every compounded vial was defective, but it reshapes what is permitted going forward.
Where compounding can still legitimately occur
Compounding does not vanish entirely. Narrow, established pathways remain: a documented clinical need for a formulation the commercial product cannot meet, such as a genuine allergy to an inactive ingredient or a required non-standard dose, can still justify patient-specific compounding under section 503A. What changed is that "it is cheaper" and "it is easier to get" are not, by themselves, lawful bases once the drug is commercially available. Legitimate compounding in 2026 is a clinical-exception route, not a parallel discount market.
The risks that were always there
Even at the height of availability, compounded GLP-1s carried risks that the branded supply chain is built to control. Reports during the boom included dosing errors from patient self-measurement and non-standard concentrations, confusion between the active drug and different salt forms such as semaglutide sodium or acetate that were never studied for efficacy, and the general uncertainty of products made outside the manufacturer's controls. Sterile injectable preparation is exacting, and quality varied across the compounding market. None of these risks were universal, but all of them were structural.
Telling a legitimate route from a grey-market one
The cleanest signal is the type of pharmacy and the basis for compounding. State-licensed 503A pharmacies and larger 503B outsourcing facilities operate under real oversight and, post-shortage, under tighter constraints on what they may prepare. A telehealth offer promising cheap "compounded semaglutide" to anyone who fills out a form, with no individualized clinical rationale, is operating on the basis that ended with the shortage. Products marketed as "research" semaglutide or tirzepatide are a separate and more concerning category entirely, sitting outside the pharmacy system altogether. Our guide on evaluating a peptide vendor and the article on compounded semaglutide versus Wegovy go further into how to read these distinctions.
Where this leaves patients in 2026
For someone who relied on compounded GLP-1 for cost reasons, the resolved shortage is a genuine disruption, and the honest options are narrower than they were: pursue insurance coverage where the indication qualifies, use manufacturer cash-pay or copay programs (covered in our cost breakdown), or work with a clinician on whether a documented compounding exception applies. What has not changed is the underlying advice: the branded, regulated product is the one with the safety controls and the trial data attached to it, and any lower-cost route should be weighed against what oversight it gives up.
Frequently asked questions
Is compounded semaglutide still legal in 2026?
Only in narrow circumstances. The mass-compounding that filled the shortage relied on the drug being on the FDA shortage list; once the shortage was declared resolved, that basis fell away. Patient-specific compounding for a documented clinical need can still be lawful under section 503A, but low price and convenience are not, by themselves, valid justifications when the branded drug is available.
Was compounded GLP-1 dangerous?
Not universally, but it carried structural risks the branded supply chain is designed to control: dosing errors from self-measurement, confusion with unstudied salt forms like semaglutide sodium, and variable quality in sterile preparation. Quality ranged widely across the compounding market.
What is the difference between compounded and 'research' GLP-1?
Compounded GLP-1 is prepared by a licensed pharmacy for a patient. 'Research' semaglutide or tirzepatide is sold outside the pharmacy system entirely, without the oversight that applies to compounding, and is a considerably more concerning category. See our vendor-evaluation guide for how to read those distinctions.
My telehealth provider still offers cheap compounded semaglutide. Is that fine?
Be cautious. An offer of cheap compounded GLP-1 to anyone who completes a form, with no individualized clinical rationale, is operating on the basis that ended with the shortage. A legitimate route ties compounding to a documented clinical need, not to price.
What are my options if I relied on compounded GLP-1 for cost?
The honest set is narrower now: pursue insurance coverage where your indication qualifies, use manufacturer cash-pay or copay programs, or discuss with a clinician whether a genuine compounding exception applies. Our GLP-1 cost article walks through the pricing routes in detail.
References
- U.S. FDA. FDA Drug Shortages: tirzepatide and semaglutide status and resolution notices. FDA Drug Shortages database
- U.S. FDA. Compounding and the FDA: sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/drugs/human-drug-compounding
- U.S. FDA. Medicines made with semaglutide sodium and semaglutide acetate: safety communication. https://www.fda.gov/
We update this article as new data and regulatory decisions publish. Last reviewed: July 2026.